–{•¶‚ÖƒXƒLƒbƒv

•‹³@“¡“c@‰ÀŽq@HEADLINE

ŽóÜ

@‘æ23‰ñƒoƒCƒGƒ‹zŠÂŠí•aŒ¤‹†•¬ŽóÜi2015j
@‘æ14‰ñ‘ÛSHRƒVƒ“ƒ|ƒWƒEƒ€ SHRŠw‰ïÜ (2010)
@‘æ83‰ñ“ú–{–ò—Šw‰ï”N‰ï—DG”­•\Ü (2010)
@‘æ45‰ñ‚ŒŒˆ³ŠÖ˜AŽ¾Š³ƒ‚ƒfƒ‹Šw‰ïŠŒ´Ü (2009)
@‘æ18‰ñ“ú–{zŠÂ–ò—Šw‰ïYoung Investigator's Award (2008)
@‘æ14‰ñ“¿“‡ˆãŠw‰ïÜ (2005)

Žå—v˜_•¶


œ Kakino, A., Fujita, Y., Nakano, A., Horiuchi, S. and Sawamura, T.: Developmental endothelial locus-1 (Del-1) inhibits oxidized low-density lipoprotein activity by direct binding, and its overexpression attenuates atherogenesis in mice. Circ J, @80:2541-2549, 2016
œ Yokoyama, C., Aoyama, T., Ido, T., Kakino, A., Shiraki, T., Tanaka, T., Nishigaki, K., Hasegawa, A., Fujita, Y., Sawamura, T. and Minatoguchi, S.: Deletion of LOX-1 protects against heart failure induced by doxorubicin. PLoS One, 11:e0154994, 2016.
œ Yamamoto, K., Kakino, A., Takeshita, H., Hayashi, N., Li, L., Nakano, A., Hanasaki-Yamamoto, H., Fujita, Y., Imaizumi, Y., Toyama-Yokoyama, S., Nakama, C., Kawai, T., Takeda, M., Hongyo, K., Oguro, R., Maekawa, Y., Itoh, N., Takami, Y., Onishi, M., Takeya, Y., Sugimoto, K., Kamide, K., Nakagami, H., Ohishi, M., Kurtz, TW., Sawamura, T., Rakugi, H.: Oxidized LDL (oxLDL) activates the angiotensin II type 1 receptor by binding to the lectin-like oxLDL receptor. FASEB J, 29:3342-3356, 2015 
œ Okamura, T., Sekikawa, A., Sawamura, T., Kadowaki, T., Barinas-Mitchell, E., Mackey, R.H., Kadota, A., Evans, R.W., Edmundowicz, D., Higashiyama, A., Nakamura, Y., Abbott, R.D., Miura, K., Fujiyoshi, A., Fujita, Y., Murakami, Y., Miyamatsu, N., Kakino, A., Maegawa, H., Murata, K., Horie, M., Mitsunami, K., Kashiwagi, A., Kuller, L.H., Ueshima, H.; ERA JUMP Study Group.: LOX-1 ligands containing apolipoprotein B and carotid intima-media thickness in middle-aged community-dwelling US Caucasian and Japanese men. Atherosclerosis, 229:240-245, 2013
œ Takanabe-Mori, R., Ono, K., Wada, H., Takaya, T., Ura, S., Yamakage, H., Satoh-Asahara, N., Shimatsu, A., Takahashi, Y., Fujita, M., Fujita, Y., Sawamura, T., Hasegawa, K.: Lectin-like oxidized low-density lipoprotein receptor-1 plays an important role in vascular inflammation in current smokers. J Atheroscler Thromb, 20:585-590, 2013
œ Ishikawa, M., Ito, H., Akiyoshi, M., Kume, N., Yoshitomi, H., Mitsuoka, H., Tanida, S., Murata, K., Shibuya, H., Kasahara, T., Kakino, A., Fujita, Y., Sawamura, T., Yasuda, T., Nakamura, T.: Lectin-like oxidized low-density lipoprotein receptor 1 signal is a potent biomarker and therapeutic target for human rheumatoid arthritis. Arthritis Rheum, 64:1024-1034, 2012
œ Fujita, Y., Yamaguchi, S., Kakino, A., Iwamoto, S., Yoshimoto, R., Sawamura, T.: Lectin-like oxidized LDL receptor 1 is involved in CRP-mediated complement activation. Clin Chem, 57:1398-1405, 2011
œ  Iwamoto, S., Fujita, Y., Kakino, A., Yanagida, K., Matsuda, H., Yoshimoto, R., Sawamura, T.: An alternative protein standard to measure activity of LOX-1 ligand containing apoB (LAB) - utilization of anti-LOX-1 single- chain antibody fused to apoB fragment. J Atheroscler Thromb, 18:818-828, 2011
œ  Nishizuka, T., Fujita, Y., Sato, Y., Nakano, A., Kakino, A., Ohshima, S., Kanda, T., Yoshimoto, R., Sawamura, T.: Procyanidins are potent inhibitors of LOX-1: a new player in the French Paradox. Proc Jpn Acad Ser B Phys Biol Sci, 87:104-113, 2011
œ Matsumoto, T., Fujita, M., Sawamura, T., Kakino, A., Sato, Y., Fujita, Y., Matsuda, H., Nakanishi, M., Uchida, K., Nakae, I., Kanda, H., Yoshida, A., Miwa, K., Hayashi, H., Mitsunami, K., Horie, M.: Pitavastatin reduces lectin-like oxidized low-density lipoprotein receptor-1 ligands in hypercholesterolemic humans. Lipids, 45:329-335, 2010
œ Nakano, A., Inoue, N., Sato, Y., Nishimichi, N., Takikawa, K., Fujita, Y., Kakino, A., Otsui, K., Yamaguchi, S., Matsuda, H., Sawamura, T.: LOX-1 mediates vascular lipid retention under hypertensive state. J Hypertens, 28:1273-1280, 2010
œ Takaya, T., Wada, H., Morimoto, T., Sunagawa, Y., Kawamura, T., Takanabe-Mori, R., Shimatsu, A., Fujita, Y., Sato, Y., Fujita, M., Kimura, T., Sawamura, T., Hasegawa, K.: Left ventricular expression of lectin-like oxidized low-density lipoprotein receptor-1 in failing rat hearts. Circ J, 74:723-729, 2010
œ Inoue, N., Okamura, T., Kokubo, Y., Fujita, Y., Sato, Y., Nakanishi, M., Yanagida, K., Kakino, A., Iwamoto, S., Watanabe, M., Ogura, S., Otsui, K., Matsuda, H., Uchida, K., Yoshimoto, R., Sawamura, T.: LOX index, a novel predictive biochemical marker for coronary heart disease and stroke. Clin Chem, 56:550-558, 2010
œ Fujita, Y., Kakino, A., Harada-Shiba, M., Sato, Y., Otsui, K., Yoshimoto, R., Sawamura, T.: C-reactive protein uptake by macrophage cell line via class-A scavenger receptor. Clin Chem, 56:478-481, 2010
œ Sugimoto, K., Ishibashi, T., Sawamura, T., Inoue, N., Kamioka, M., Uekita, H., Ohkawara, H., Sakamoto, T., Sakamoto, N., Okamoto, Y., Takuwa, Y., Kakino, A., Fujita, Y., Tanaka, T., Teramoto, T., Maruyama, Y., Takeishi, Y.: LOX-1-MT1-MMP axis is crucial for RhoA and Rac1 activation induced by oxidized low-density lipoprotein in endothelial cells. Cardiovasc Res, 84:127-136, 2009
œ Fujita, Y., Kakino, A., Nishimichi, N., Yamaguchi, S., Sato, Y., Machida, S., Cominacini, L., Delneste, Y., Matsuda, H., Sawamura, T.: Oxidized LDL receptor LOX-1 binds to C-reactive protein and mediates its vascular effects. Clin Chem, 55:285-294, 2009
œ Hu, C., Chen, J., Dandapat, A., Fujita, Y., Inoue, N., Kawase, Y., Jishage, K., Suzuki, H., Li, D., Hermonat, P.L., Sawamura, T., Mehta, J.L.: LOX-1 abrogation reduces myocardial ischemia-reperfusion injury in mice. J Mol Cell Cardiol, 44:76-83, 2008
œ Izawa, Y., Yoshizumi, M., Ishizawa, K., Fujita, Y., Kondo, S., Kagami, S., Kawazoe, K., Tsuchiya, K., Tomita, S., Tamaki, T.: Big mitogen-activated protein kinase 1 (BMK1)/extracellular signal regulated kinase 5 (ERK5) is involved in platelet-derived growth factor (PDGF)-induced vascular smooth muscle cell migration. Hypertens Res, 30:1107-1117, 2007
œ Hu, C., Dandapat, A., Chen, J., Fujita, Y., Inoue, N., Kawase, Y., Jishage, K., Suzuki, H., Sawamura, T., Mehta, J.L.: LOX-1 deletion alters signals of myocardial remodeling immediately after ischemia-reperfusion. Cardiovasc Res, 76:292-302, 2007
œ Fujita, Y., Izawa, Y., Ali, N., Kanematsu, Y., Tsuchiya, K., Hamano, S., Tamaki, T., Yoshizumi, M.: Pramipexole protects against H2O2-induced PC12 cell death. Naunyn Schmiedebergs Arch Pharmacol, 372:257-266, 2006
œ Fujita, Y., Yoshizumi, M., Izawa, Y., Ali, N., Ohnishi, H., Kanematsu, Y., Ishizawa, K., Tsuchiya, K., Tamaki, T.: Transactivation of fetal liver kinase-1/kinase-insert domain-containing receptor by lysophosphatidylcholine induces vascular endothelial cell proliferation. Endocrinology, 147:1377-1385, 2006
œ Hinagata, J., Kakutani, M., Fujii, T., Naruko, T., Inoue, N., Fujita, Y., Mehta, J.L., Ueda, M., Sawamura, T.: Oxidized LDL receptor LOX-1 is involved in neointimal hyperplasia after balloon arterial injury in a rat model. Cardiovasc Res, 69:263-271, 2006
œ Ishizawa, K., Izawa, Y., Ito, H., Miki, C., Miyata, K., Fujita, Y., Kanematsu, Y., Tsuchiya, K., Tamaki, T., Nishiyama, A., Yoshizumi, M.: Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation. Hypertension, 46:1046-1052, 2005
œ Ali, N., Yoshizumi, M., Fujita, Y., Izawa, Y., Kanematsu, Y., Ishizawa, K., Tsuchiya, K., Yano, S., Sone,S., Tamaki, T.: A novel Src kinase inhibitor, M475271, inhibits VEGF-induced human umbilical vein endothelial cell proliferation and migration. J Pharmacol Sci, 98:130-141, 2005
œ Izawa, Y., Yoshizumi, M., Fujita, Y., Ali, N., Kanematsu, Y., Ishizawa, K., Tsuchiya, K., Obata, T., Ebina, Y., Tomita, S., Tamaki, T.: ERK1/2 activation by angiotensin II inhibits insulin-induced glucose uptake in vascular smooth muscle cells. Exp Cell Res, 308:291-299, 2005
œ Kyaw, M., Yoshizumi, M., Tsuchiya, K., Izawa, Y., Kanematsu, Y., Fujita, Y., Ali, N., Ishizawa, K., Yamauchi, A., Tamaki, T.: Antioxidant effects of stereoisomers of N-acetylcysteine (NAC), L-NAC and D-NAC, on angiotensin II-stimulated MAP kinase activation and vascular smooth muscle cell proliferation. J Pharmacol Sci, 95:483-486, 2004
œKyaw, M., Yoshizumi, M., Tsuchiya, K., Kagami, S., Izawa, Y., Fujita, Y., Ali, N., Kanematsu, Y., Toida, K., Ishimura, K., Tamaki, T.: Src and Cas are essentially but differentially involved in angiotensin II-stimulated migration of vascular smooth muscle cells via extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase activation. Mol Pharmacol, 65:832-841, 2004
œ Ali, N., Yoshizumi, M., Tsuchiya, K., Kyaw, M., Fujita, Y., Izawa,Y., Abe, S., Kanematsu, Y., Kagami, S., Tamaki, T.: Ebselen inhibits p38 mitogen-activated protein kinase-mediated endothelial cell death by hydrogen peroxide. Eur J Pharmacol, 485:127-135, 2004
œ Yoshizumi, M., Fujita, Y., Izawa, Y., Suzaki, Y., Kyaw, M., Ali, N., Tsuchiya, K., Kagami, S., Yano, S., Sone, S., Tamaki, T.: Ebselen inhibits tumor necrosis factor-alpha-induced c-Jun N-terminal kinase activation and adhesion molecule expression in endothelial cells. Exp Cell Res, 292:1-10, 2004
œ Yoshizumi, M., Kogame, T., Suzaki, Y., Fujita, Y., Kyaw, M., Kirima, K., Ishizawa, K., Tsuchiya, K., Kagami, S., Tamaki, T.: Ebselen attenuates oxidative stress-induced apoptosis via the inhibition of the c-Jun N-terminal kinase and activator protein-1 signalling pathway in PC12 cells. Br J Pharmacol, 136:1023-1032, 2002





Š‘®Šw‰ï

“ú–{–ò—Šw‰ï
“ú–{zŠÂ–ò—Šw‰ï
“ú–{–òŠw‰ï
“ú–{“®–¬d‰»Šw‰ï
‚ŒŒˆ³ŠÖ˜AŽ¾Š³ƒ‚ƒfƒ‹Šw‰ï
“ú–{SŒŒŠÇ“à•ª”å‘ãŽÓŠw‰ï
“ú–{¶—Šw‰ï




ƒoƒi[ƒXƒy[ƒX